The clinical impact of SPECT/PET co-registration with MRI in patients with brain tumors
- Memorial Sloan-Kettering Cancer Center, New York, NY (United States); and others
We wanted to evaluate the clinical impact of co-registering SPECT and PET images with MRI (Gd-DTPA) in brain tumor patients. 81 patients with known or suspected brain tumors had 168 SPECT and/or PET scans which were difficult to interpret were coregistered with MRI. A modified Pellizari/Chen surface matching algorithm was used to fit the SPECT/PET and MR images. Impact of the technique on interpretation of the scans was defined as (A) no effect, (B) moderate effect (better localize abnormal uptake to suspected tumor and distinguish normal activity from tumor), (C) basis for final interpretation (distinguish tumor from necrosis, localize biopsy site, find occult tumor, grading of tumor). Impact on patient management was defined as (A) no effect, (B) altered diagnostic/treatment decision (continuation of conservative care, or justify chemo or radiation), (C) basis for treatment (direct biopsy, surgery, and/or radiation).
- OSTI ID:
- 197883
- Report Number(s):
- CONF-940605-; ISSN 0161-5505; TRN: 95:007029-0006
- Journal Information:
- Journal of Nuclear Medicine, Vol. 35, Issue Suppl.5; Conference: 41. annual meeting of the Society of Nuclear Medicine, Orlando, FL (United States), 5-8 Jun 1994; Other Information: PBD: May 1994
- Country of Publication:
- United States
- Language:
- English
Similar Records
Can brain thallium 201 SPECT substitute for F-18-FDG PET in detecting recurrent brain tumor in the presence of radiation necrosis; correlation with biopsy/surgery results
Comparison of thallium 201 (TL) SPECT and F-18 fluoro-deoxyglucose (FDG) PET in the evaluation of MRI lesions in patients with gliomas after therapy